Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
NCT04213261Phase 3Active, not recruiting
- Sponsor
- Castle Creek Biosciences
- Start
- Jun 2020
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of dabocemagene autoficel in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Castle Creek Biosciences. Started Jun 2020; status: active, not recruiting.
02
Drugs
dabocemagene autoficel
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04213261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213261.